Table 1.

Characteristics of the included studies in this systematic review of outcomes of KTx patients with C3GN.

C3GN among KTx Recipients
Authors	Type of Study	Patients (n)	Age at Time of Diagnosis/Transplant, Median (Years)	Females (n)	Time to Dialysis or KTX, Median (Months)	Type of KTX	Complement Abnormality	Median Follow-Up (Months)	Median Time from KTx to Recurrence (Months)	Recurrence	Rituximab, Graft Failure (n)	Eculizumab, Graft Failure (n)	PLEX + Steroids, Graft Failure (n)	No Therapy for Recurrence, Graft Failure (n)	Graft Failure, Total (n)
Regunathan-Shenk et al., 2019 [48]	Cohort	12	22	3	48	LRKTx, 7 LUKTx, 3 DDKTx, 2	CD46, 1 C3Nef, 2 C5Nef, 1 None, 1 Not done, 7	76	-	8, yes 2, probable2, no	0	3, 1 (1 treated with Eculizumab + PLEX)	1, 0	9, 2	3
Zand et al., 2014 [50]	Cohort	21	20.8	9	42.3	LKTx, 17 DDKTx, 4	-	73.9	28	14, yes 7, no	3, 2	0,0	1 + plus autologous peripheral stem cell transplant, 0 1 treated with steroids alone, 1	10, 0	7
Frangou et al., 2019 [71]	Cohort	17	46.7	4	-	LRKTx, 3 LUKTx, 3 DDKTx, 11	CFHR5, 17	157	37	3, yes 9, probable	0,0	0,0	2, 2	14, 3	5
Serra et al., 2018 [72]	Case series	3 (de novo)	66	1	-	DDKTx, 3	None, 2 Anti-CFH ab, 1	-	72	3 de novo	1, 1	0	0	2, 2	3
Wong et al., 2016 [73]	Case series	4 (familial)	26.5	2	-	DDKTx, 4	-	-	97	2, yes	0	0	0	2, 1	1
Alasfar et al., 2016 [74]	Cohort	5	37.4	3	-	DDKTx,1 LUKTx, 1	-	63.6	-	2, yes	0	1,0	0	1, 1	1
Jeantet et al., 2017 [75]	Cohort	9	-	-	-	-	-	-	1.5	9, yes	0	9, 2	0	0	2
Bomback et al., 2012 [32]	Case series	2	21	2	-	-	C3Nef, 2	-	2.5	2	-	2, 0 (1 treated with Eculizumab + PLEX, steroids)	1, 0	0	0

Abbreviations: KTX, kidney transplant; LKTx, living donor kidney transplant, LRKTx, living-related kidney transplant; LUKTx, living unrelated kidney transplant; DDKTx, deceased donor kidney transplant; PLEX, plasma exchange.